TARA Share Price | Protara Therapeutics, Inc. Stock Analysis & Recommendation

Q: Is Protara Therapeutics, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Protara Therapeutics, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and weekly Dow Theory also showing a mildly bearish signal. While the MACD is mildly bullish on both weekly and monthly time frames, the overall sentiment is tempered by the Bollinger Bands showing a mildly bearish trend on the monthly. In terms of performance, the stock has underperformed relative to the S&P 500 across multiple periods, with a year-to-date return of -39.20% compared to the S&P's 12.22%, and a significant decline of -82.49% over the past five years against the S&P's 96.61%.

Q: How big is Protara Therapeutics, Inc.?

Market Cap: As of Jun 18, Protara Therapeutics, Inc. has a market capitalization of 118.06 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Protara Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -45.41 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 167.13 million and total assets of 181.45 million.

Q: What does Protara Therapeutics, Inc. do?

Overview: Protara Therapeutics, Inc. is a clinical-stage company focused on developing treatments for rare and specialty diseases within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Profit: -12 Million (Quarterly Results - Mar 2025) Market cap: USD 118.06 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.78 Return on Equity: -28.66% Price to Book: 0.74Contact Details: Address: 1 Little West 12Th Street, NEW YORK NY: 10014 Tel: 1 646 8440337 Fax: 1 302 6555049 Website: https://protaratx.com/

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

947.9 k

Shareholding (Mar 2026)

FII

9.28%

Held by 35 FIIs

DII

84.95%

Held by 17 DIIs

Promoter

5.77%

Is Protara Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Protara Therapeutics, Inc. is in a mildly bearish trend, with daily moving averages and weekly Dow Theory indicating bearishness, despite a mildly bullish MACD; the stock has underperformed the S&P 500 significantly, with a year-to-date return of -39.20% and a five-year decline of -82.49%.

View full answer

How big is Protara Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Protara Therapeutics, Inc. has a market capitalization of 118.06 million, with net sales of 0.00 million and a net profit of -45.41 million over the latest four quarters. The company reported shareholder's funds of 167.13 million and total assets of 181.45 million as of Dec 24.

View full answer

What does Protara Therapeutics, Inc. do?

22-Jun-2025

Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare and specialty diseases. As of March 2025, it has a market cap of $118.06 million and reported a net profit loss of $12 million.

View full answer

Who are in the management team of Protara Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Protara Therapeutics, Inc. includes Chairman Luke Beshar, CEO Jesse Shefferman, and several directors: Barry Flannelly, Roger Garceau, Richard Levy, Gregory Sargen, and Michael Solomon. They oversee the company's strategic direction and operations.

View full answer

Compare Protara Therapeutics, Inc. with Similar Stocks

Cocrystal Pharma, Inc.Palatin Technologies, Inc.Entera Bio Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 267 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.79

Return on Equity

-29.24%

Price to Book

1.36

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-18 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-20.62%

6 Months

-25.77%

1 Year

38.26%

2 Years

110.74%

3 Years

70.25%

4 Years

21.18%

5 Years

-59.73%

Protara Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-33.95%

EBIT to Interest (avg)

-43.24

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.78

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.36

EV to EBIT

-1.75

EV to EBITDA

-1.76

EV to Capital Employed

2.68

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-153.32%

ROE (Latest)

-29.24%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 19 Schemes (11.78%)

Foreign Institutions

Held by 35 Foreign Institutions (9.28%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -49.58% vs -7.21% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.50",
          "val2": "-14.00",
          "chgp": "-39.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.80",
          "val2": "-11.90",
          "chgp": "-49.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -28.70% vs -10.40% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-64.20",
          "val2": "-48.80",
          "chgp": "-31.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-57.40",
          "val2": "-44.60",
          "chgp": "-28.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-19.50

-14.00

-39.29%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-17.80

-11.90

-49.58%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -49.58% vs -7.21% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-64.20

-48.80

-31.56%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-57.40

-44.60

-28.70%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -28.70% vs -10.40% in Dec 2024

All Annual Results

Company CV

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Its product pipeline includes TARA 002 and IV choline chloride for injection. TARA 002 is its lead program focused on the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an enzyme replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).

Company Coordinates

Company Details

1 Little West 12Th Street , NEW YORK NY : 10014

Tel: 1 646 84403371 646 8440337

https://protaratx.com/

Registrar Details